BlackRock’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-625,420
| Closed | -$24.8M | – | 5722 |
|
|
2026
Q1 | $24.8M | Buy |
625,420
+32,816
| +6% | +$839K | ﹤0.01% | 2942 |
|
|
2025
Q4 | $14.8M | Buy |
592,604
+184,218
| +45% | +$4.67M | ﹤0.01% | 3256 |
|
|
2025
Q3 | $9.9M | Buy |
408,386
+27,261
| +7% | +$485K | ﹤0.01% | 3460 |
|
|
2025
Q2 | $5.01M | Sell |
381,125
-18,841
| -5% | -$239K | ﹤0.01% | 3777 |
|
|
2025
Q1 | $5.75M | Sell |
399,966
-100,958
| -20% | -$1.65M | ﹤0.01% | 3593 |
|
|
2024
Q4 | $8.39M | Sell |
500,924
-58,796
| -11% | -$974K | ﹤0.01% | 3515 |
|
|
2024
Q3 | $8.95M | Buy |
559,720
+95,098
| +20% | +$1.16M | ﹤0.01% | 3465 |
|
|
2024
Q2 | $4.2M | Buy |
464,622
+82,160
| +21% | +$779K | ﹤0.01% | 3748 |
|
|
2024
Q1 | $4.32M | Buy |
382,462
+36,191
| +10% | +$343K | ﹤0.01% | 3729 |
|
|
2023
Q4 | $2.76M | Buy |
346,271
+20,428
| +6% | +$137K | ﹤0.01% | 3919 |
|
|
2023
Q3 | $2.11M | Buy |
325,843
+31,343
| +11% | +$214K | ﹤0.01% | 3974 |
|
|
2023
Q2 | $1.82M | Buy |
294,500
+1,840
| +0.6% | +$8.73K | ﹤0.01% | 4087 |
|
|
2023
Q1 | $1.13M | Sell |
292,660
-17,381
| -6% | -$63.6K | ﹤0.01% | 4299 |
|
|
2022
Q4 | $961K | Buy |
310,041
+16,530
| +6% | +$61.3K | ﹤0.01% | 4423 |
|
|
2022
Q3 | $1.18M | Sell |
293,511
-8,404
| -3% | -$38.4K | ﹤0.01% | 4419 |
|
|
2022
Q2 | $1.47M | Buy |
301,915
+25,397
| +9% | +$162K | ﹤0.01% | 4378 |
|
|
2022
Q1 | $2.48M | Sell |
276,518
-10,720
| -4% | -$97.7K | ﹤0.01% | 4301 |
|
|
2021
Q4 | $3.23M | Buy |
+287,238
| New | +$3.86M | ﹤0.01% | 4195 |
|
|
2021
Q3 | – | Sell |
-4,992
| Closed | -$110K | – | 5619 |
|
|
2021
Q2 | $110K | Buy |
+4,992
| New | +$117K | ﹤0.01% | 5022 |
|
BlackRock's CNTA Position: Q2 2026 in Review
BlackRock sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 625,420 shares — an estimated $24.8M sold.
BlackRock first reported a position in CNTA in Q2 2021 and held it in 19 quarters. The position peaked at $24.8M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- BlackRock reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- BlackRock sold 625,420 Centessa Pharmaceuticals shares in Q2 2026, an estimated $24.8M.
- BlackRock first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 19 quarters.
- BlackRock's Centessa Pharmaceuticals position peaked at $24.8M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.